Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the commercial launch of Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets, the same as the sanofi-aventis U.S.... [read full story]
|
RELATED
|
|
The allergy drug had annual US sales of $293 million as of June 30. Globes' correspondent4 Nov 09 10:37 A day after issuing its third quarter results, generic pharmaceuticals giant ) said it is releasing a generic version of...
JERUSALEM, Nov 03, 2009 (BUSINESS WIRE) -- Teva Pharmaceutical Industries Ltd. (TEVA) announced today the commercial launch of Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets,...
JERUSALEM----Teva Pharmaceutical Industries Ltd. announced today the commercial launch of Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets, the same as the sanofi-aventis U.S....
JERUSALEM - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the commercial launch of Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets, the same as the...
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the commercial launch of Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets, the same as the sanofi-aventis U.S....
Finance, Banking & Insurance, International Relations, Corporate Legal Issues, Agencies of the European Union, Investing & Markets, Industrial Property, Intergovernmental Organizations, Industrial Patents, Pharmaceuticals, Financial Markets, Investing, Intellectual Property, Innovation, Corporate Performance, Stock Markets, Teva Pharmaceuticals, Barr Pharmaceuticals, European Union, European Medicines Agency
